Abstract | BACKGROUND: There are limited published data on the impact of treatment on the health-related quality of life (HRQOL) in individuals with autistic disorder. OBJECTIVE: The aim of this study was to evaluate the impact of aripiprazole on HRQOL in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder. METHODS: This post hoc analysis assessed data from two 8-week, double-blind, randomized, placebo-controlled studies that compared the efficacy of aripiprazole (fixed-dose study, 5, 10, and 15 mg/d; flexible-dose study, 2-15 mg/d) with placebo in the treatment of irritability associated with autistic disorder. HRQOL was assessed at baseline and week 8 using 3 Pediatric Quality of Life Inventory (PedsQL™) scales. Clinically relevant improvement in HRQOL was determined using an accepted distribution-based criterion-1 standard error of measurement. RESULTS: In total, 316 patients were randomly assigned to receive treatment with aripiprazole (fixed-dose study, 166; flexible-dose study, 47) or placebo (fixed-dose study, 52; flexible-dose study, 51). Aripiprazole was associated with significantly greater improvement than placebo in PedsQL combined-scales total score (difference, 7.8; 95% CI, 3.8-11.8; P < 0.001) and in 3 PedsQL scale scores (differences [95% CI]: Emotional Functioning, 7.8 [3.4-12.2]; Social Functioning, 6.2 [0.7-11.8]; Cognitive Functioning, 9.3 [3.8-14.9]; all, P < 0.05). Patients who received aripiprazole were significantly more likely than those who received placebo to have a clinically meaningful improvement on the combined-scales total score (odds ratio [OR] = 1.9; 95% CI, 1.0-3.3; P < 0.05), Emotional Functioning scale (OR = 2.2; 95% CI, 1.2-4.0; P < 0.05) and Social Functioning scale (OR = 2.2; 95% CI, 1.2-4.1; P < 0.05), and were significantly less likely to experience deterioration (OR: 0.3, 95% CI: 0.1-0.8; P < 0.05) when "Stable" was used as the reference group. CONCLUSIONS: The findings from the present post hoc analysis suggest that aripiprazole was associated with improved HRQOL, as assessed using 3 PedsQL scales, in pediatric patients with irritability associated with autistic disorder.
|
Authors | James W Varni, Benjamin L Handen, Patricia K Corey-Lisle, Zhenchao Guo, George Manos, Diane K Ammerman, Ronald N Marcus, Randall Owen, Robert D McQuade, William H Carson, Suja Mathew, Raymond Mankoski |
Journal | Clinical therapeutics
(Clin Ther)
Vol. 34
Issue 4
Pg. 980-92
(Apr 2012)
ISSN: 1879-114X [Electronic] United States |
PMID | 22444782
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved. |
Chemical References |
- Antipsychotic Agents
- Piperazines
- Quinolones
- Aripiprazole
|
Topics |
- Adolescent
- Antipsychotic Agents
(administration & dosage, therapeutic use)
- Aripiprazole
- Autistic Disorder
(drug therapy)
- Child
- Dose-Response Relationship, Drug
- Humans
- Irritable Mood
(drug effects)
- Piperazines
(administration & dosage, therapeutic use)
- Quality of Life
- Quinolones
(administration & dosage, therapeutic use)
- Randomized Controlled Trials as Topic
|